Abbvie ((ABBV)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a study titled ‘Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of ABBV-6628 in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration.’ The study aims to evaluate the safety and movement of the drug ABBV-6628 in the bodies of adults with geographic atrophy, a severe form of age-related macular degeneration. This research is significant as it could lead to new treatment options for this debilitating eye condition.
The study tests ABBV-6628, an investigational monoclonal antibody fragment, administered via intravitreal injection. It is designed to treat geographic atrophy by potentially slowing disease progression.
This interventional study is randomized and follows a sequential model with quadruple masking to ensure unbiased results. Its primary purpose is treatment-focused, aiming to assess the drug’s safety and efficacy.
The study began on August 12, 2025, with primary completion expected in approximately 22 months, followed by a 3-month follow-up. The last update was submitted on September 4, 2025, indicating ongoing recruitment and progress.
The study’s outcome could impact AbbVie’s stock performance positively if results show promising efficacy and safety, potentially boosting investor confidence. The competitive landscape includes other treatments like SYFOVRE, which is also being tested in this study.
The study is ongoing, and further details are available on the ClinicalTrials portal.